Reuters logo
BRIEF-Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its plasminogen replacement therapy
August 29, 2017 / 10:49 AM / 25 days ago

BRIEF-Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its plasminogen replacement therapy

Aug 29 (Reuters) - Prometic Life Sciences Inc

* Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its plasminogen replacement therapy

* Prometic life sciences - ‍U.S. FDA granted Rare Pediatric Disease Designation to Prometic’s Ryplazimä, a plasminogen replacement therapy Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below